Interstitial Disease in Systemic Sclerosis

Handbook of Systemic Autoimmune Diseases

Volumn 2, Issue , 2004, Pages 181-207

  Goh, Nicole S ^a   du Bois, Roland M ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34548774394     PISSN: 15715078     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1571-5078(04)02010-0     Document Type: Review

References (302)

1. Abraham D.J., Vancheeswaran R., Dashwood M.R., Rajkumar V.S., Pantelidis P., Xu S.W., du Bois R.M., and Black C.M. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am. J. Pathol. 151 3 (1997) 831-841
2. Abu-Shakra M., Guillemin F., and Lee P. Cancer in systemic sclerosis. Arthritis Rheum. 36 4 (1993) 460-464
3. Agelli M., and Wahl S.M. Cytokines and fibrosis. Clin. Exp. Rheumatol. 4 4 (1986) 379-388
4. Akesson A., Scheja A., Lundin A., and Wollheim F.A. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum. 37 5 (1994) 729-735
5. Akira M. Computed tomography and pathologic findings in fulminant forms of idiopathic interstitial pneumonia. J. Thorac. Imag. 14 2 (1999) 76-84
6. Altman R.D., Medsger Jr. T.A., Bloch D.A., and Michel B.A. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum. 34 4 (1991) 403-413
7. American Thoracic Society/European Respiratory Society 2002. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This Joint Statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS Board of Directors, June 2001 and by The ERS Executive Committee, June 2001 Am. J. Respir. Crit. Care Med. 165 (2), 277-304.
8. Anaya J.M., Diethelm L., Ortiz L.A., Gutierrez M., Citera G., Welsh R.A., and Espinoza L.R. Pulmonary involvement in rheumatoid arthritis. Semin. Arthritis Rheum. 24 4 (1995) 242-254
9. Andreev V.C. Skin manifestations in visceral cancer. Curr. Prob. Dermatol. 8 (1978) 1-168
10. Arnett F.C., Reveille J.D., Wilson R.W., Provost T.T., and Bias W.B. Systemic lupus erythematosus: current state of the genetic hypothesis. Semin. Arthritis Rheum. 14 1 (1984) 24-35
11. Arnett F.C., Bias W.B., McLean R.H., Engel M., Duvic M., Goldstein R., Freni-Titulaer L., McKinley T.W., and Hochberg M.C. Connective tissue disease in southeast Georgia. A community based study of immunogenetic markers and autoantibodies. J. Rheumatol. 17 8 (1990) 1029-1035
12. Arnett F.C., Howard R.F., Tan F., Moulds J.M., Bias W.B., Durban E., Cameron H.D., Paxton G., Hodge T.J., Weathers P.E., and Reveille J.D. Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Association with an Amerindian HLA haplotype. Arthritis Rheum. 39 8 (1996) 1362-1370
13. Arnett F.C., Reveille J.D., Goldstein R., Pollard K.M., Leaird K., Smith E.A., Leroy E.C., and Fritzler M.J. Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis. Arthritis Rheum. 39 7 (1996) 1151-1160
14. Arnett F.C., Cho M., Chatterjee S., Aguilar M.B., Reveille J.D., and Mayes M.D. Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum. 44 6 (2001) 1359-1362
15. Arroliga A.C., Podell D.N., and Matthay R.A. Pulmonary manifestations of scleroderma. J. Thorac. Imag. 7 2 (1992) 30-45
16. Artlett C.M., Smith J.B., and Jimenez S.A. Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis. N. Engl. J. Med. 338 17 (1998) 1186-1191
17. Artlett C.M., Cox L.A., Ramos R.C., Dennis T.N., Fortunato R.A., Hummers L.K., Jimenez S.A., and Smith J.B. Increased microchimeric CD4+ T lymphocytes in peripheral blood from women with systemic sclerosis. Clin. Immunol. 103 3 Pt 1 (2002) 303-308
18. Artlett C.M., Rasheed M., Russo-Stieglitz K.E., Sawaya H.H., and Jimenez S.A. Influence of prior pregnancies on disease course and cause of death in systemic sclerosis. Ann. Rheum. Dis. 61 4 (2002) 346-350
19. Asano Y., Ihn H., Yamane K., Kubo M., and Tamaki K. Impaired Smad 7-Smurf-mediated negative regulation of TGF-beta signaling in scleroderma fibroblasts. J. Clin. Invest. 113 2 (2004) 253-264
20. Asano Y., Ihn H., Yamane K., Yazawa N., Kubo M., Fujimoto M., and Tamaki K. Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. Arthritis Rheum. 44 6 (2001) 1363-1369
21. Atamas S.P., and White B. Interleukin 4 in systemic sclerosis: not just an increase. Clin. Diagn. Lab. Immunol. 6 5 (1999) 658-659
22. Atamas S.P., Luzina I.G., Choi J., Tsymbalyuk N., Carbonetti N.H., Singh I.S., Trojanowska M., Jimenez S.A., and White B. Pulmonary and activation-regulated chemokine stimulates collagen production in lung fibroblasts. Am. J. Respir. Cell. Mol. Biol. 29 6 (2003) 743-749
23. Avila J.J., Lympany P.A., Pantelidis P., Welsh K.I., Black C.M., and du Bois R.M. Fibronectin gene polymorphisms associated with fibrosing alveolitis in systemic sclerosis. Am. J. Respir. Cell Mol. Biol. 20 1 (1999) 106-112
24. Bar J., Ehrenfeld M., Rozenman J., Perelman M., Sidi Y., and Gur H. Pulmonary-renal syndrome in systemic sclerosis. Semin. Arthritis Rheum. 30 6 (2001) 403-410
25. Bedrossian C.W., Sussman J., Conklin R.H., and Kahan B. Azathioprine-associated interstitial pneumonitis. Am. J. Clin. Pathol. 82 2 (1984) 148-154
26. Beebe J.L., Lacey Jr. J.V., Mayes M.D., et al. Reproductive history, oral contraceptive use, estrogen replacement therapy and the risk of developing scleroderma. Arthritis Rheum. 40 Suppl. (1997) S100
27. Behr J., Vogelmeier C., Beinert T., Meurer M., Krombach F., Konig G., and Fruhmann G. Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. Am. J. Respir. Crit. Care Med. 154 2 Pt 1 (1996) 400-406
28. Bernstein R.M., Steigerwald J.C., and Tan E.M. Association of antinuclear and antinucleolar antibodies in progressive systemic sclerosis. Clin. Exp. Immunol. 48 1 (1982) 43-51
29. Bianchi D.W., Zickwolf G.K., Weil G.J., Sylvester S., and DeMaria M.A. Male fetal progenitor cells persist in maternal blood for as long as 27 years postpartum. Proc. Natl. Acad. Sci. USA 93 2 (1996) 705-708
30. Bielefeld P., Meyer P., Caillot D., Dalac S., Camus P., Tavernier C., Couillaut G., Chalopin J.M., and Besancenot J.F. Systemic scleroderma and cancers: 21 cases and review of the literature. Rev. Med. Int. 17 10 (1996) 810-813
31. Black C.M. Scleroderma-clinical aspects. J. Intern. Med. 234 2 (1993) 115-118
32. Black K.A., Zilko P.J., Dawkins R.L., Armstrong B.K., and Mastaglia G.L. Cancer in connective tissue disease. Arthritis Rheum. 25 9 (1982) 1130-1133
33. Blaszczyk M., Jarzabek-Chorzelska M., Jablonska S., Chorzelski T., Kolacinska-Strasz Z., Beutner E.H., and Kumar V. Autoantibodies to nucleolar antigens in systemic scleroderma: clinical correlations. Br. J. Dermatol. 123 4 (1990) 421-430
34. Boehler A., Vogt P., Speich R., Weder W., and Russi E.W. Bronchiolitis obliterans in a patient with localised scleroderma treated with d-penicillamine. Eur. Respir. J. 9 6 (1996) 1317-1319
35. Bolster M.B., Ludwicka A., Sutherland S.E., Strange C., and Silver R.M. Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthritis Rheum. 40 4 (1997) 743-751
36. Bouros D., Wells A.U., Nicholson A.G., Colby T.V., Polychronopoulos V., Pantelidis P., Haslam P.L., Vassilakis D.A., Black C.M., and du Bois R.M. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am. J. Respir. Crit. Care. Med. 165 12 (2002) 1581-1586
37. Bramwell B. Diffuse scleroderma: its frequency; its occurrence in stonemasons; its treatment by fibrolysin-elevations of temperature due to fibrolysin injections. Edinburgh Med. J. 12 (1914) 387
38. Bridges A.J., Hsu K.C., Dias-Arias A.A., and Chechani V. Bronchiolitis obliterans organizing pneumonia and scleroderma. J. Rheumatol. 19 7 (1992) 1136-1140
39. Briggs D.C., Vaughan R.W., Welsh K.I., Myers A., du Bois R.M., and Black C.M. Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet 338 8768 (1991) 661-662
40. Buchbinder R., Forbes A., Hall S., Dennett X., and Giles G. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann. Intern. Med. 134 12 (2001) 1087-1095
41. Bunn C.C., Denton C.P., Shi-Wen X., Knight C., and Black C.M. Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br. J. Rheumatol 37 1 (1998) 15-20
42. Cambrey A.D., Harrison N.K., Dawes K.E., Southcott A.M., Black C.M., du Bois R.M., Laurent G.J., and McAnulty R.J. Increased levels of endothelin-1 in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro. Am. J. Respir. Cell. Mol. Biol. 11 4 (1994) 439-445
43. Chaer R.A., Massad M.G., Evans A., Olopade C., and Varga J. Systemic sclerosis complicated by diffuse alveolar hemorrhage. Med. Sci. Monit. 7 5 (2001) 1013-1015
44. Chandran G., Smith M., Ahern M.J., and Roberts-Thomson P.J. A study of scleroderma in South Australia: prevalence, subset characteristics and nailfold capillaroscopy. Aust. N. Z. J. Med. 25 6 (1995) 688-694
45. Chang M., Wang R.J., Yangco D.T., Sharp G.C., Komatireddy G.R., and Hoffman R.W. Analysis of autoantibodies against RNA polymerases using immunoaffinity-purifed RNA polymerase I, II, and III antigen in an enzyme-linked immunosorbent assay. Clin. Immunol. Immunopathol. 89 1 (1998) 71-78
46. Chatterjee S., Severson R.K., Weiss L.K., Kau T.Y., and Mayes M.D. Risk of malignancy in Scleroderma [abstract]. Arthritis Rheum. 43 Suppl (2000) S315
47. Chow W.H., Gridley G., Mellemkjaer L., McLaughlin J.K., Olsen J.H., and Fraumeni Jr. J.F. Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark. Cancer Causes Control 6 1 (1995) 9-13
48. Clements P.J., Furst D.E., Wong W.K., Mayes M., White B., Wigley F., Weisman M.H., Barr W., Moreland L.W., Medsger Jr. T.A., Steen V., Martin R.W., Collier D., Weinstein A., Lally E., Varga J., Weiner S., Andrews B., Abeles M., and Seibold J.R. High-dose versus low-dose d-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum. 42 6 (1999) 1194-1203
49. Coker R.K., Laurent G.J., Jeffery P.K., du Bois R.M., Black C.M., and McAnulty R.J. Localisation of transforming growth factor beta1 and beta3 mRNA transcripts in normal and fibrotic human lung. Thorax. 56 7 (2001) 549-556
50. Collins C.D., Wells A.U., Hansell D.M., Morgan R.A., MacSweeney J.E., du Bois R.M., and Rubens M.B. Observer variation in pattern type and extent of disease in fibrosing alveolitis on thin section computed tomography and chest radiography. Clin. Radiol. 49 4 (1994) 236-240
51. Cooper Jr. J.A., White D.A., and Matthay R.A. Drug-induced pulmonary disease. Part 1. Cytotoxic drugs. Am. Rev. Respir. Dis. 133 2 (1986) 321-340
52. Corrin B., Butcher D., McAnulty B.J., du Bois R.M., Black C.M., Laurent G.J., and Harrison N.K. Immunohistochemical localization of transforming growth factor-beta 1 in the lungs of patients with systemic sclerosis, cryptogenic fibrosing alveolitis and other lung disorders. Histopathology 24 2 (1994) 145-150
53. Crilly A., Hamilton J., Clark C.J., Jardine A., and Madhok R. Analysis of transforming growth factor beta1 gene polymorphisms in patients with systemic sclerosis. Ann. Rheum. Dis. 61 8 (2002) 678-681
54. D'Angelo W.A., Fries J.F., Masi A.T., and Shulman L.E. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am. J. Med. 46 3 (1969) 428-440
55. Daniil Z.D., Gilchrist F.C., Nicholson A.G., Hansell D.M., Harris J., Colby T.V., and du Bois R.M. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am. J. Respir. Crit. Care. Med. 160 3 (1999) 899-905
56. Davas E.M., Peppas C., Maragou M., Alvanou E., Hondros D., and Dantis P.C. Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin. Rheumatol. 18 6 (1999) 455-461
57. Davis M.D., and Ahmed I. Ovarian malignancy in patients with dermatomyositis and polymyositis: a retrospective analysis of fourteen cases. J. Am. Acad. Dermatol. 37 5 Pt 1 (1997) 730-733
58. de Clerck L.S., Dequeker J., Francx L., and Demedts M. d-penicillamine therapy and interstitial lung disease in scleroderma. A long-term follow-up study. Arthritis Rheum. 30 6 (1987) 643-650
59. Deguchi Y., and Kishimoto S. Spontaneous activation of transforming growth factor-beta gene transcription in broncho-alveolar mononuclear cells of individuals with systemic autoimmune diseases with lung involvement. Lupus 1 1 (1991) 27-30
60. DeMarco P.J., Weisman M.H., Seibold J.R., Furst D.E., Wong W.K., Hurwitz E.L., Mayes M., White B., Wigley F., Barr W., Moreland L., Medsger Jr. T.A., Steen V., Martin R.W., Collier D., Weinstein A., Lally E., Varga J., Weiner S.R., Andrews B., Abeles M., and Clements P.J. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose d-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum. 46 11 (2002) 2983-2989
61. Denton C.P., Xu S., Black C.M., and Pearson J.D. Scleroderma fibroblasts show increased responsiveness to endothelial cell-derived IL-1 and bFGF. J. Invest. Dermatol. 108 3 (1997) 269-274
62. de Rooij D.J., van de Putte L.B., Habets W.J., and van Venrooij W.J. Marker antibodies in scleroderma and polymyositis: clinical associations. Clin. Rheumatol. 8 2 (1989) 231-237
63. Desai S.R., Veeraraghavan S., Goh N.S., Hansell D.M., Nikolakopolou A., Colby T.V., Denton C.P., Black C., du Bois R.M., and Wells A.U. CT features of lung disease in systemic sclerosis: a comparison with the appearances in idiopathic pulmonary fibrosis and non-specific interstitial pneumonitis. Radiology (2003) in press
64. Desmouliere A., Geinoz A., Gabbiani F., and Gabbiani G. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J. Cell. Biol. 122 1 (1993) 103-111
65. Dick T., Mierau R., Bartz-Bazzanella P., Alavi M., Stoyanova-Scholz M., Kindler J., and Genth E. Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis. Ann. Rheum. Dis. 61 2 (2002) 121-127
66. Dong C., Zhu S., Wang T., Yoon W., Li Z., Alvarez R.J., ten Dijke P., White B., Wigley F.M., and Goldschmidt-Clermont P.J. Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc. Natl Acad. Sci. USA 99 6 (2002) 3908-3913
67. Dubaybo B.A., and Thet L.A. Effect of transforming growth factor beta on synthesis of glycosaminoglycans by human lung fibroblasts. Exp. Lung Res. 16 5 (1990) 389-403
68. du Bois E.L., Chandor S., Friou G.J., and Bischel M. Progressive systemic sclerosis (PSS) and localized scleroderma (morphea) with positive LE cell test and unusual systemic manifestations compatible with systemic lupus erythematous (SLE): presentation of 14 cases including one set of identical twins, one with scleroderma and the other with SLE. Review of the literature. Medicine (Baltimore) 50 3 (1971) 199-222
69. Duncan M.R., and Berman B. Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. J. Invest. Dermatol. 97 4 (1991) 686-692
70. Duncan S.C., and Winkelmann R.K. Cancer and scleroderma. Arch. Dermatol. 115 8 (1979) 950-955
71. Edworthy S.M., Martin L., Barr S.G., Birdsell D.C., Brant R.F., and Fritzler M.J. A clinical study of the relationship between silicone breast implants and connective tissue disease. J. Rheumatol. 25 2 (1998) 254-260
72. Endo H., Hosono T., and Kondo H. Antineutrophil cytoplasmic autoantibodies in 6 patients with renal failure and systemic sclerosis. J. Rheumatol. 21 5 (1994) 864-870
73. Englert H., Small-McMahon J., Chambers P., O'Connor H., Davis K., Manolios N., White R., Dracos G., and Brooks P. Familial risk estimation in systemic sclerosis. Aust. N. Z. J. Med. 29 1 (1999) 36-41
74. Falkner D., Wilson J., Medsger Jr. T.A., and Morel P.A. HLA and clinical associations in systemic sclerosis patients with anti-Th/To antibodies. Arthritis Rheum. 41 1 (1998) 74-80
75. Falkner D., Wilson J., Fertig N., Clawson K., Medsger Jr. T.A., and Morel P.A. Studies of HLA-DR and DQ alleles in systemic sclerosis patients with autoantibodies to RNA polymerases and U3-RNP (fibrillarin). J. Rheumatol. 27 5 (2000) 1196-1202
76. Fallon P.G., Richardson E.J., McKenzie G.J., and McKenzie A.N. Schistosome infection of transgenic mice defines distinct and contrasting pathogenic roles for IL-4 and IL-13: IL-13 is a profibrotic agent. J. Immunol. 164 5 (2000) 2585-2591
77. Fanning G.C., Welsh K.I., Bunn C., Du B.R., and Black C.M. HLA associations in three mutually exclusive autoantibody subgroups in UK systemic sclerosis patients. Br. J. Rheumatol. 37 2 (1998) 201-207
78. Feghali C.A., and Wright T.M. Epidemiologic and clinical study of twins with scleroderma (abstract). Arthritis Rheum. 38 (1995) S308
79. Ferri C., Zakrzewska K., Longombardo G., Giuggioli D., Storino F.A., Pasero G., and Azzi A. Parvovirus B19 infection of bone marrow in systemic sclerosis patients. Clin. Exp. Rheumatol. 17 6 (1999) 718-720
80. Ferri C., Valentini G., Cozzi F., Sebastiani M., Michelassi C., La Montagna G., Bullo A., Cazzato M., Tirri E., Storino F., Giuggioli D., Cuomo G., Rosada M., Bombardieri S., Todesco S., and Tirri G. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 81 2 (2002) 139-153
81. Fine A., and Goldstein R.H. The effect of transforming growth factor-beta on cell proliferation and collagen formation by lung fibroblasts. J. Biol. Chem. 262 8 (1987) 3897-3902
82. Flaherty K.R., Toews G.B., Travis W.D., Colby T.V., Kazerooni E.A., Gross B.H., Jain A., Strawderman III R.L., Paine R., Flint A., Lynch III J.P., and Martinez F.J. Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur. Respir. J. 19 2 (2002) 275-283
83. Flaherty K.R., Colby T.V., Travis W.D., Toews G.B., Mumford J., Murray S., Thannickal V.J., Kazerooni E.A., Gross B.H., Lynch III J.P., and Martinez F.J. Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease. Am. J. Respir. Crit. Care. Med. 167 10 (2003) 1410-1415
84. Flaherty K.R., Thwaite E.L., Kazerooni E.A., Gross B.H., Toews G.B., Colby T.V., Travis W.D., Mumford J.A., Murray S., Flint A., Lynch III J.P., and Martinez F.J. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax 58 2 (2003) 143-148
85. Flores R.H., Stevens M.B., and Arnett F.C. Familial occurrence of progressive systemic sclerosis and systemic lupus erythematosus. J. Rheumatol. 11 3 (1984) 321-323
86. Forbes A.M., Woodrow J.C., Verbov J.L., and Graham R.M. Carcinoma of breast and scleroderma: four further cases and a literature review. Br. J. Rheumatol. 28 1 (1989) 65-69
87. Fries K.M., Felch M.E., and Phipps R.P. Interleukin-6 is an autocrine growth factor for murine lung fibroblast subsets. Am. J. Respir. Cell. Mol. Biol. 11 5 (1994) 552-560
88. Fujita J., Yoshinouchi T., Ohtsuki Y., Tokuda M., Yang Y., Yamadori I., Bandoh S., Ishida T., Takahara J., and Ueda R. Non-specific interstitial pneumonia as pulmonary involvement of systemic sclerosis. Ann. Rheum. Dis. 60 3 (2001) 281-283
89. Furuse S., Fujii H., Kaburagi Y., Fujimoto M., Hasegawa M., Takehara K., and Sato S. Serum concentrations of the CXC chemokines interleukin 8 and growth-regulated oncogene-alpha are elevated in patients with systemic sclerosis. J. Rheumatol. 30 7 (2003) 1524-1528
90. Galindo M., Santiago B., Rivero M., Rullas J., Alcami J., and Pablos J.L. Chemokine expression by systemic sclerosis fibroblasts: abnormal regulation of monocyte chemoattractant protein 1 expression. Arthritis Rheum. 44 6 (2001) 1382-1386
91. Giacomelli R., Valentini G., Salsano F., Cipriani P., Sambo P., Conforti M.L., Fulminis A., De Luca A., Farina G., Candela M., Generini S., De Francisci A., Tirri E., Proietti M., Bombardieri S., Gabrielli A., Tonietti G., and Cerinic M.M. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J. Rheumatol. 29 4 (2002) 731-736
92. Gibbons G.H., and Dzau V.J. Endothelial function in vascular remodelling. In: Warren J.B. (Ed). The Endothelium: An Introduction to Current Research (1990), Wiley-Liss, New York 81-93
93. Gilchrist F.C., Bunn C., Foley P.J., Lympany P.A., Black C.M., Welsh K.I., and du Bois R.M. Class II HLA associations with autoantibodies in scleroderma: a highly significant role for HLA-DP. Genes Immun. 2 2 (2001) 76-81
94. Gladman D.D., Keystone E.C., Baron M., Lee P., Cane D., and Mervert H. Increased frequency of HLA-DR5 in scleroderma. Arthritis Rheum. 24 6 (1981) 854-856
95. Goh N.S., Veeraraghavan S., Desai S.R., Hansell D.M., Anagnostopoulos C., Denton C.P., Black C.M., du Bois R.M., and Wells A.U. The prognostic significance of technetium labeled diethylenetriamine pentacetate (99mTc-DTPA) clearance in patients with the fibrosing alveolitis of systemic sclerosis (FASSc). Am. J. Respir. Crit. Care Med. 167 7 (2003) A475
96. Goh N.S., Veeraraghavan S., Desai S.R., Hansell D.M., Denton C., Black C.M., du Bois R.M., and Wells A.U. Fibrosing alveolitis in systemic sclerosis (FASSc): a prognostic evaluation of computed tomography, pulmonary function indices, bronchoalveolar lavage cellularity and clinical data. Am. J. Respir. Crit. Care Med. 167 7 (2003) A475
97. Green R.J., Ruoss S.J., Kraft S.A., Duncan S.R., Berry G.J., and Raffin T.A. Pulmonary capillaritis and alveolar hemorrhage. Update on diagnosis and management. Chest 110 5 (1996) 1305-1316
98. Greenwald G.I., Tashkin D.P., Gong H., Simmons M., Duann S., Furst D.E., and Clements P. Longitudinal changes in lung function and respiratory symptoms in progressive systemic sclerosis. Prospective study. Am. J. Med. 83 1 (1987) 83-92
99. Griffin M.T., Robb J.D., and Martin J.R. Diffuse alveolar haemorrhage associated with progressive systemic sclerosis. Thorax 45 11 (1990) 903-904
100. Griffiths B., Miles S., Moss H., Robertson R., Veale D., and Emery P. Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J. Rheumatol. 29 11 (2002) 2371-2378
101. Hagberg B., Leonhardt T., and Skogh M. Familial occurrence of collagen diseases: progressive systemic sclerosis and systemic lupus erythematosus. Acta Med. Scand. 169 (1961) 727
102. Hahn B.H. Antibodies to DNA. N. Engl. J. Med. 338 19 (1998) 1359-1368
103. Hall J.M., Lingenfelter P., Adams S.L., Lasser D., Hansen J.A., and Bean M.A. Detection of maternal cells in human umbilical cord blood using fluorescence in situ hybridization. Blood 86 7 (1995) 2829-2832
104. Hamada H., Kohno N., Akiyama M., and Hiwada K. Monitoring of serum KL-6 antigen in a patient with radiation pneumonia. Chest 101 3 (1992) 858-860
105. Harrison N.K., Glanville A.R., Strickland B., Haslam P.L., Corrin B., Addis B.J., Lawrence R., Millar A.B., Black C.M., and Turner-Warwick M. Pulmonary involvement in systemic sclerosis: the detection of early changes by thin section CT scan, bronchoalveolar lavage and 99mTc-DTPA clearance. Respir. Med. 83 5 (1989) 403-414
106. Harrison N.K., McAnulty R.J., Haslam P.L., Black C.M., and Laurent G.J. Evidence for protein oedema, neutrophil influx, and enhanced collagen production in lungs of patients with systemic sclerosis. Thorax 45 8 (1990) 606-610
107. Harrison N.K., Argent A.C., McAnulty R.J., Black C.M., Corrin B., and Laurent G.J. Collagen synthesis and degradation by systemic sclerosis lung fibroblasts. Responses to transforming growth factor-beta. Chest 99 Suppl. 3 (1991) 71S-72S
108. Harrison N.K., Myers A.R., Corrin B., Soosay G., Dewar A., Black C.M., du Bois R.M., and Turner-Warwick M. Structural features of interstitial lung disease in systemic sclerosis. Am. Rev. Respir. Dis. 144 3 Pt 1 (1991) 706-713
109. Harrison N.K., Cambrey A.D., Myers A.R., Southcott A.M., Black C.M., du Bois R.M., Laurent G.J., and McAnulty R.J. Insulin-like growth factor-I is partially responsible for fibroblast proliferation induced by bronchoalveolar lavage fluid from patients with systemic sclerosis. Clin. Sci. (London) 86 2 (1994) 141-148
110. Harvey G., Black C., Maddison P., and McHugh N. Characterization of antinucleolar antibody reactivity in patients with systemic sclerosis and their relatives. J. Rheumatol. 24 3 (1997) 477-484
111. Harvey G.R., Butts S., Rands A.L., Patel Y., and McHugh N.J. Clinical and serological associations with anti-RNA polymerase antibodies in systemic sclerosis. Clin. Exp. Immunol. 117 2 (1999) 395-402
112. Hasegawa M., Fujimoto M., Kikuchi K., and Takehara K. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J. Rheumatol. 24 2 (1997) 328-332
113. Hasegawa M., Fujimoto M., Kikuchi K., and Takehara K. Elevated serum tumor necrosis factor-alpha levels in patients with systemic sclerosis: association with pulmonary fibrosis. J. Rheumatol. 24 4 (1997) 663-665
114. Hasegawa M., Sato S., Ihn H., and Takehara K. Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis. Rheumatology (Oxford) 38 7 (1999) 612-617
115. Hasegawa M., Sato S., and Takehara K. Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1alpha (MIP-1alpha) and MIP-1beta) in patients with systemic sclerosis: MCP-1 and MIP-1alpha may be involved in the development of pulmonary fibrosis. Clin. Exp. Immunol. 117 1 (1999) 159-165
116. Hata R., Akai J., Kimura A., Ishikawa O., Kuwana M., and Shinkai H. Association of functional microsatellites in the human type I collagen alpha2 chain (COL1A2) gene with systemic sclerosis. Biochem. Biophys. Res. Commun. 272 1 (2000) 36-40
117. Helfrich D.J., Banner B., Steen V.D., and Medsger Jr. T.A. Normotensive renal failure in systemic sclerosis. Arthritis Rheum. 32 9 (1989) 1128-1134
118. Henry P.A., Atamas S.P., Yurovsky V.V., Luzina I., Wigley F.M., and White B. Diversity and plasticity of the anti-DNA topoisomerase I autoantibody response in scleroderma. Arthritis Rheum. 43 12 (2000) 2733-2742
119. Hieshima K., Imai T., Baba M., Shoudai K., Ishizuka K., Nakagawa T., Tsuruta J., Takeya M., Sakaki Y., Takatsuki K., Miura R., Opdenakker G., Van Damme J., Yoshie O., and Nomiyama H. A novel human CC chemokine PARC that is most homologous to macrophage-inflammatory protein-1 alpha/LD78 alpha and chemotactic for T lymphocytes, but not for monocytes. J. Immunol. 159 3 (1997) 1140-1149
120. Hildebrandt S., Jackh G., Weber S., and Peter H.H. A long-term longitudinal isotypic study of anti-topoisomerase I autoantibodies. Rheumatol. Int. 12 6 (1993) 231-234
121. Hill C.L., Zhang Y., Sigurgeirsson B., Pukkala E., Mellemkjaer L., Airio A., Evans S.R., and Felson D.T. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 357 9250 (2001) 96-100
122. Hill C.L., Nguyen A.M., Roder D., and Roberts-Thomson P. Risk of cancer in patients with scleroderma: a population based cohort study. Ann. Rheum. Dis. 62 8 (2003) 728-731
123. Hochberg M.C., and Perlmutter D.L. The association of augmentation mammoplasty with connective tissue disease, including systematic sclerosis (scleroderma): a meta-analysis. Curr. Top. Microbiol. Immunol. 210 (1996) 411-417
124. Ihn H., and Tamaki K. Oncostatin M stimulates the growth of dermal fibroblasts via a mitogen-activated protein kinase-dependent pathway. J. Immunol. 165 4 (2000) 2149-2155
125. Ihn H., Leroy E.C., and Trojanowska M. Oncostatin M stimulates transcription of the human alpha2(I) collagen gene via the Sp1/Sp3-binding site. J. Biol. Chem. 272 39 (1997) 24666-24672
126. Jacobsen S., Halberg P., Ullman S., van Venrooij W.J., Hoier-Madsen M., Wiik A., and Petersen J. Clinical features and serum antinuclear antibodies in 230 Danish patients with systemic sclerosis. Br. J. Rheumatol. 37 1 (1998) 39-45
127. Janowsky E.C., Kupper L.L., and Hulka B.S. Meta-analyses of the relation between silicone breast implants and the risk of connective-tissue diseases. N. Engl. J. Med. 342 11 (2000) 781-790
128. Jelaska A., and Korn J.H. Role of apoptosis and transforming growth factor beta1 in fibroblast selection and activation in systemic sclerosis. Arthritis Rheum. 43 10 (2000) 2230-2239
129. Jimenez S.A., and Gershwin M.E. Animal models of systemic sclerosis. In: Clements P.J., and Furst D.E. (Eds). Systemic sclerosis. 1st ed. (1996), Williams & Wilkins, Baltimore 251-273
130. Johnson M.A., Kwan S., Snell N.J., Nunn A.J., Darbyshire J.H., and Turner-Warwick M. Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 44 4 (1989) 280-288
131. Johnson R.W., Tew M.B., and Arnett F.C. The genetics of systemic sclerosis. Curr. Rheumatol. Rep. 4 2 (2002) 99-107
132. Kadono T., Kikuchi K., Ihn H., Takehara K., and Tamaki K. Increased production of interleukin 6 and interleukin 8 in scleroderma fibroblasts. J. Rheumatol. 25 2 (1998) 296-301
133. Kallenbach J., Prinsloo I., and Zwi S. Progressive systemic sclerosis complicated by diffuse pulmonary haemorrhage. Thorax 32 6 (1977) 767-770
134. Kallenberg C.G., Jansen H.M., Elema J.D., and The T.H. Steroid-responsive interstitial pulmonary disease in systemic sclerosis. Monitoring by bronchoalveolar lavage. Chest 86 3 (1984) 489-492
135. Kamb M.L., Murphy J.J., Jones J.L., Caston J.C., Nederlof K., Horney L.F., Swygert L.A., Falk H., and Kilbourne E.M. Eosinophilia-myalgia syndrome in l-tryptophan-exposed patients. JAMA 267 1 (1992) 77-82
136. Kane G.C., Varga J., Conant E.F., Spirn P.W., Jimenez S., and Fish J.E. Lung involvement in systemic sclerosis (scleroderma): relation to classification based on extent of skin involvement or autoantibody status. Respir. Med. 90 4 (1996) 223-230
137. Katzenstein A.L., and Fiorelli R.F. Nonspecific interstitial pneumonia/fibrosis. Histologic features and clinical significance. Am. J. Surg. Pathol. 18 2 (1994) 136-147
138. Katzenstein A.L., and Myers J.L. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am. J. Respir. Crit Care Med. 157 4 Pt 1 (1998) 1301-1315
139. Kikuchi K., Kadono T., Furue M., and Tamaki K. Tissue inhibitor of metalloproteinase 1 (TIMP-1) may be an autocrine growth factor in scleroderma fibroblasts. J. Invest. Dermatol. 108 3 (1997) 281-284
140. Kim D.S., Yoo B., Lee J.S., Kim E.K., Lim C.M., Lee S.D., Koh Y., Kim W.S., Kim W.D., Colby T.V., and Kitiaichi M. The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumonia. Sarcoidosis. Vasc. Diffuse Lung Dis. 19 2 (2002) 121-127
141. Kinsella M.B., Smith E.A., Miller K.S., Leroy E.C., and Silver R.M. Spontaneous production of fibronectin by alveolar macrophages in patients with scleroderma. Arthritis Rheum. 32 5 (1989) 577-583
142. Kirk T.Z., Mark M.E., Chua C.C., Chua B.H., and Mayes M.D. Myofibroblasts from scleroderma skin synthesize elevated levels of collagen and tissue inhibitor of metalloproteinase (TIMP-1) with two forms of TIMP-1. J. Biol. Chem. 270 7 (1995) 3423-3428
143. Kissin E.Y., Lemaire R., Korn J.H., and Lafyatis R. Transforming growth factor beta induces fibroblast fibrillin-1 matrix formation. Arthritis Rheum. 46 11 (2002) 3000-3009
144. Kohno N., Akiyama M., Kyoizumi S., Hakoda M., Kobuke K., and Yamakido M. Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. Jpn. J. Clin. Oncol. 18 3 (1988) 203-216
145. Kohno N., Kyoizumi S., Awaya Y., Fukuhara H., Yamakido M., and Akiyama M. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest 96 1 (1989) 68-73
146. Kuhn C., and McDonald J.A. The roles of the myofibroblast in idiopathic pulmonary fibrosis. Ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis. Am. J. Pathol. 138 5 (1991) 1257-1265
147. Kuhn III C., Boldt J., King Jr. T.E., Crouch E., Vartio T., and McDonald J.A. An immunohistochemical study of architectural remodelling and connective tissue synthesis in pulmonary fibrosis. Am. Rev. Respir. Dis. 140 6 (1989) 1693-1703
148. Kumagai Y., Shiokawa Y., Medsger Jr. T.A., and Rodnan G.P. Clinical spectrum of connective tissue disease after cosmetic surgery. Observations on eighteen patients and a review of the Japanese literature. Arthritis Rheum. 27 1 (1984) 1-12
149. Kuwana M., Kaburaki J., Mimori T., Tojo T., and Homma M. Autoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis. J. Clin. Invest. 91 4 (1993) 1399-1404
150. Kuwana M., Kaburaki J., Okano Y., Inoko H., and Tsuji K. The HLA-DRand DQ genes control the autoimmune response to DNA topoisomerase I in systemic sclerosis (scleroderma). J. Clin. Invest. 92 3 (1993) 1296-1301
151. Kuwana M., Kaburaki J., Okano Y., Tojo T., and Homma M. Clinical and prognostic associations based on serum antinuclear antibodies in
152. Kuwana M., Kaburaki J., Mimori T., Kawakami Y., and Tojo T. Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis. Arthritis Rheum. 43 5 (2000) 1074-1084
153. Kuwana M., Kimura K., Hirakata M., Kawakami Y., and Ikeda Y. Differences in autoantibody response to Th/To between systemic sclerosis and other autoimmune diseases. Ann. Rheum. Dis. 61 9 (2002) 842-846
154. Laing T.J., Gillespie B.W., Toth M.B., Mayes M.D., Gallavan Jr. R.H., Burns C.J., Johanns J.R., Cooper B.C., Keroack B.J., Wasko M.C., Lacey Jr. J.V., and Schottenfeld D. Racial differences in scleroderma among women in Michigan. Arthritis Rheum. 40 4 (1997) 734-742
155. Launay D., Hebbar M., Hatron P.Y., Michon-Pasturel U., Queyrel V., Hachulla E., and Devulder B. Relationship between parity and clinical and biological features in patients with systemic sclerosis. J. Rheumatol. 28 3 (2001) 509-513
156. Leask A., Holmes A., and Abraham D.J. Connective tissue growth factor: a new and important player in the pathogenesis of fibrosis. Curr. Rheumatol. Rep. 4 2 (2002) 136-142
157. Leroy E.C., Black C., Fleischmajer R., Jablonska S., Krieg T., Medsger Jr. T.A., Rowell N., and Wollheim F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J. Rheumatol. 15 2 (1988) 202-205
158. Lo Y.M., Lo E.S., Watson N., Noakes L., Sargent I.L., Thilaganathan B., and Wainscoat J.S. Two-way cell traffic between mother and fetus: biologic and clinical implications. Blood 88 11 (1996) 4390-4395
159. Ludwicka A., Ohba T., Trojanowska M., Yamakage A., Strange C., Smith E.A., Leroy E.C., Sutherland S., and Silver R.M. Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma. J. Rheumatol. 22 10 (1995) 1876-1883
160. Lunardi C., Bason C., Navone R., Millo E., Damonte G., Corrocher R., and Puccetti A. Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nat. Med. 6 10 (2000) 1183-1186
161. Luzina I.G., Atamas S.P., Wise R., Wigley F.M., Xiao H.Q., and White B. Gene expression in bronchoalveolar lavage cells from scleroderma patients. Am. J. Respir. Cell Mol. Biol. 26 5 (2002) 549-557
162. Ma Y., Seneviratne C.K., and Koss M. Idiopathic pulmonary fibrosis and malignancy. Curr. Opin. Pulm. Med. 7 5 (2001) 278-282
163. MacDonald S.L., Rubens M.B., Hansell D.M., Copley S.J., Desai S.R., du Bois R.M., Nicholson A.G., Colby T.V., and Wells A.U. Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparative appearances at and diagnostic accuracy of thin-section CT. Radiology 221 3 (2001) 600-605
164. Maddison P.J., Stephens C., Briggs D., Welsh K.I., Harvey G., Whyte J., McHugh N., and Black C.M. Connective tissue disease and autoantibodies in the kindreds of 63 patients with systemic sclerosis. The United Kingdom Systemic Sclerosis Study Group. Medicine (Baltimore) 72 2 (1993) 103-112
165. Maeda M., Ichiki Y., Aoyama Y., and Kitajima Y. Surfactant protein D (SP-D) and systemic scleroderma (SSc). J. Dermatol. 28 9 (2001) 467-474
166. Malik S.W., Myers J.L., DeRemee R.A., and Specks U. Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Am. J. Respir. Crit Care Med. 154 6 Pt 1 (1996) 1851-1856
167. Maloney S., Smith A., Furst D.E., Myerson D., Rupert K., Evans P.C., and Nelson J.L. Microchimerism of maternal origin persists into adult life. J. Clin. Invest. 104 1 (1999) 41-47
168. Maoz C.R., Langevitz P., Livneh A., Blumstein Z., Sadeh M., Bank I., Gur H., and Ehrenfeld M. High incidence of malignancies in patients with dermatomyositis and polymyositis: an 11-year analysis. Semin. Arthritis Rheum. 27 5 (1998) 319-324
169. Marguerie C., Bunn C.C., Copier J., Bernstein R.M., Gilroy J.M., Black C.M., So A.K., and Walport M.J. The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-Scl. Medicine (Baltimore) 71 6 (1992) 327-336
170. Masi A.T., Rodnan G.P., and Medsger Jr. T.A. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 23 (1980) 581-590
171. Massague J. How cells read TGF-beta signals. Nat. Rev. Mol. Cell Biol. 1 3 (2000) 169-178
172. Mattingly P.C., and Mowat A.G. Rapidly progressive scleroderma associated with carcinoma of the oesophagus. Ann. Rheum. Dis. 38 2 (1979) 177-178
173. Mayes M.D., Lacey Jr. J.V., Beebe-Dimmer J., Gillespie B.W., Cooper B., Laing T.J., and Schottenfeld D. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 48 8 (2003) 2246-2255
174. McAnulty R.J., Campa J.S., Cambrey A.D., and Laurent G.J. The effect of transforming growth factor beta on rates of procollagen synthesis and degradation in vitro. Biochim. Biophys. Acta 1091 2 (1991) 231-235
175. McHugh N.J., Whyte J., Artlett C., Briggs D.C., Stephens C.O., Olsen N.J., Gusseva N.G., Maddison P.J., Black C.M., and Welsh K. Anti-centromere antibodies (ACA) in systemic sclerosis patients and their relatives: a serological and HLA study. Clin. Exp. Immunol. 96 2 (1994) 267-274
176. Medsger T.A. Systemic sclerosis (scleroderma): clinical aspect. In: Koopman W.J. (Ed). Arthritis and Allied Conditions. A Textbook of Rheumatology vol. 2 (1997), Williams and Wilkins, Philadelphia 1433-1465
177. Meyers J.L. Pathology of drug-induced lung disease. In: Katzenstein A.A., and Askin F.B. (Eds). Katzenstein and Askin's Surgical Pathology of Non-neoplastic Lung Disease. 3rd ed (1997), Saunders, Philadelphia 81-111
178. Minai O.A., Dweik R.A., and Arroliga A.C. Manifestations of scleroderma pulmonary disease. Clin. Chest Med. 19 4 (1998) pp. 713-7ix
179. Mogulkoc N., Brutsche M.H., Bishop P.W., Murby B., Greaves M.S., Horrocks A.W., Wilson M., McCullough C., Prescott M., and Egan J.J. Pulmonary (99m)Tc-DTPA aerosol clearance and survival in usual interstitial pneumonia (UIP). Thorax 56 12 (2001) 916-923
180. Moore B.B., Paine III R., Christensen P.J., Moore T.A., Sitterding S., Ngan R., Wilke C.A., Kuziel W.A., and Toews G.B. Protection from pulmonary fibrosis in the absence of CCR2 signaling. J. Immunol. 167 8 (2001) 4368-4377
181. Morel P.A., Chang H.J., Wilson J.W., Conte C., Falkner D., Tweardy D.J., and Medsger Jr. T.A. HLA and ethnic associations among systemic sclerosis patients with anticentromere antibodies. Hum. Immunol. 42 1 (1995) 35-42
182. Morgan C., Knight C., Lunt M., Black C.M., and Silman A.J. Predictors of end stage lung disease in a cohort of patients with scleroderma. Ann. Rheum. Dis. 62 2 (2003) 146-150
183. Nakajima H., Harigai M., Hara M., Hakoda M., Tokuda H., Sakai F., Kamatani M., and Kashiwazaki S. KL-6 as a novel serum marker for interstitial pneumonia associated with collagen diseases. J. Rheumatol. 27 5 (2000) 1164-1170
184. Nelson J.L., Furst D.E., Maloney S., Gooley T., Evans P.C., Smith A., Bean M.A., Ober C., and Bianchi D.W. Microchimerism and HLA-compatible relationships of pregnancy in scleroderma. Lancet 351 9102 (1998) 559-562
185. Nicholson A.G., Colby T.V., du Bois R.M., Hansell D.M., and Wells A.U. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am. J. Respir. Crit Care Med. 162 6 (2000) 2213-2217
186. Nicholson A.G., Colby T.V., and Wells A.U. Histopathological approach to patterns of interstitial pneumonia in patient with connective tissue disorders. Sarcoidosis. Vasc. Diffuse. Lung Dis. 19 1 (2002) 10-17
187. Nietert P.J., Sutherland S.E., Silver R.M., Pandey J.P., Knapp R.G., Hoel D.G., and Dosemeci M. Is occupational organic solvent exposure a risk factor for scleroderma?. Arthritis Rheum. 41 6 (1998) 1111-1118
188. Nietert P.J., Sutherland S.E., Silver R.M., Pandey J.P., and Dosemeci M. Solvent oriented hobbies and the risk of systemic sclerosis. J. Rheumatol. 26 11 (1999) 2369-2372
189. Nishi K., Myou S., Ooka T., Fujimura M., and Matsuda T. Diffuse cutaneous systemic sclerosis associated with pan-serositis, disseminated intravascular coagulation, and diffuse alveolar haemorrhage. Respir. Med. 88 6 (1994) 471-473
190. Oddis C.V., Okano Y., Rudert W.A., Trucco M., Duquesnoy R.J., and Medsger Jr. T.A. Serum autoantibody to the nucleolar antigen PM-Scl. Clinical and immunogenetic associations. Arthritis Rheum. 35 10 (1992) 1211-1217
191. Ohba T., McDonald J.K., Silver R.M., Strange C., Leroy E.C., and Ludwicka A. Scleroderma bronchoalveolar lavage fluid contains thrombin, a mediator of human lung fibroblast proliferation via induction of platelet-derived growth factor alpha-receptor. Am. J. Respir. Cell Mol. Biol. 10 4 (1994) 405-412
192. Ohtsuka T., Miyamoto Y., Yamakage A., and Yamazaki S. Quantitative analysis of microchimerism in systemic sclerosis skin tissue. Arch. Dermatol. Res. 293 8 (2001) 387-391
193. Okano Y., Steen V.D., and Medsger Jr. T.A. Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann. Intern. Med. 119 10 (1993) 1005-1013
194. Oriente A., Fedarko N.S., Pacocha S.E., Huang S.K., Lichtenstein L.M., and Essayan D.M. Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J. Pharmacol. Exp. Ther. 292 3 (2000) 988-994
195. Owens G.R., Fino G.J., Herbert D.L., Steen V.D., Medsger Jr. T.A., Pennock B.E., Cottrell J.J., Rodnan G.P., and Rogers R.M. Pulmonary function in progressive systemic sclerosis. Comparison of CREST syndrome variant with diffuse scleroderma. Chest 84 5 (1983) 546-550
196. Pakas I., Ioannidis J.P., Malagari K., Skopouli F.N., Moutsopoulos H.M., and Vlachoyiannopoulos P.G. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J. Rheumatol. 29 2 (2002) 298-304
197. Pantelidis P., Southcott A.M., Black C.M., and du Bois R.M. Up-regulation of IL-8 secretion by alveolar macrophages from patients with fibrosing alveolitis: a subpopulation analysis. Clin. Exp. Immunol. 108 1 (1997) 95-104
198. Pantelidis P., McGrath D.S., Southcott A.M., Black C.M., and du Bois R.M. Tumour necrosis factor-alpha production in fibrosing alveolitis is macrophage subset specific. Respir. Res. 2 6 (2001) 365-372
199. Pardo A., Smith K.M., Abrams J., Coffman R., Bustos M., McClanahan T.K., Grein J., Murphy E.E., Zlotnik A., and Selman M. CCL18/DC-CK-1/PARC up-regulation in hypersensitivity pneumonitis. J. Leukoc. Biol. 70 4 (2001) 610-616
200. Peters-Golden M., Wise R.A., Hochberg M., Stevens M.B., and Wigley F.M. Incidence of lung cancer in systemic sclerosis. J. Rheumatol. 12 6 (1985) 1136-1139
201. Phan T.G., Wong R.C., and Adelstein S. Autoantibodies to extractable nuclear antigens: making detection and interpretation more meaningful. Clin. Diagn. Lab Immunol. 9 1 (2002) 1-7
202. Phillips D., Phillips B., and Mannino D. A case study and national database report of progressive systemic sclerosis and associated conditions. J. Womens Health 7 9 (1998) 1099-1104
203. Pisa F.E., Bovenzi M., Romeo L., Tonello A., Biasi D., Bambara L.M., Betta A., and Barbone F. Reproductive factors and the risk of scleroderma: an Italian case-control study. Arthritis Rheum. 46 2 (2002) 451-456
204. Postlethwaite A.E., and Seyer J.M. Stimulation of fibroblast chemotaxis by human recombinant tumor necrosis factor alpha (TNF-alpha) and a synthetic TNF-alpha 31-68 peptide. J. Exp. Med. 172 6 (1990) 1749-1756
205. Postlethwaite A.E., and Seyer J.M. Fibroblast chemotaxis induction by human recombinant interleukin-4. Identification by synthetic peptide analysis of two chemotactic domains residing in amino acid sequences 70-88 and 89-122. J. Clin. Invest. 87 6 (1991) 2147-2152
206. Postlethwaite A.E., Lachman L.B., and Kang A.H. Induction of fibroblast proliferation by interleukin-1 derived from human monocytic leukemia cells. Arthritis Rheum. 27 9 (1984) 995-1001
207. Postlethwaite A.E., Holness M.A., Katai H., and Raghow R. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J. Clin. Invest. 90 4 (1992) 1479-1485
208. Raghu G., Masta S., Meyers D., and Narayanan A.S. Collagen synthesis by normal and fibrotic human lung fibroblasts and the effect of transforming growth factor-beta. Am. Rev. Respir. Dis. 140 1 (1989) 95-100
209. Reddy R., Tan E.M., Henning D., Nohga K., and Busch H. Detection of a nucleolar 7-2 ribonucleoprotein and a cytoplasmic 8-2 ribonucleoprotein with autoantibodies from patients with scleroderma. J. Biol. Chem. 258 3 (1983) 1383-1386
210. Reimer G., Rose K.M., Scheer U., and Tan E.M. Autoantibody to RNA polymerase I in scleroderma sera. J. Clin. Invest. 79 1 (1987) 65-72
211. Reimer G., Steen V.D., Penning C.A., Medsger Jr. T.A., and Tan E.M. Correlates between autoantibodies to nucleolar antigens and clinical features in patients with systemic sclerosis (scleroderma). Arthritis Rheum. 31 4 (1988) 525-532
212. Reiser K.M., and Last J.A. Early cellular events in pulmonary fibrosis. Exp. Lung Res. 10 4 (1986) 331-355
213. Reveille J.D., Durban E., MacLeod-St Clair M.J., Goldstein R., Moreda R., Altman R.D., and Arnett F.C. Association of amino acid sequences in the HLA-DQB1 first domain with antitopoisomerase I autoantibody response in scleroderma (progressive systemic sclerosis). J. Clin. Invest. 90 3 (1992) 973-980
214. Reveille J.D., Owerbach D., Goldstein R., Moreda R., Isern R.A., and Arnett F.C. Association of polar amino acids at position 26 of the HLA-DQB1 first domain with the anticentromere autoantibody response in systemic sclerosis (scleroderma). J. Clin. Invest. 89 4 (1992) 1208-1213
215. Reveille J.D., Fischbach M., McNearney T., Friedman A.W., Aguilar M.B., Lisse J., Fritzler M.J., Ahn C., and Arnett F.C. Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin. Arthritis Rheum. 30 5 (2001) 332-346
216. American College of Rhematology Ad Hoc Committee on Immunological Testing Guidelines, Reveille J.D., and Solomon D.H. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum. 49 3 (2003) 399-412
217. Rom W.N., Basset P., Fells G.A., Nukiwa T., Trapnell B.C., and Crystal R.G. Alveolar macrophages release an insulin-like growth factor I-type molecule. J. Clin. Invest. 82 5 (1988) 1685-1693
218. Rosas V., Conte J.V., Yang S.C., Gaine S.P., Borja M., Wigley F.M., White B., and Orens J.B. Lung transplantation and systemic sclerosis. Ann. Transplant. 5 3 (2000) 38-43
219. Rosenthal A.K., McLaughlin J.K., Linet M.S., and Persson I. Scleroderma and malignancy: an epidemiological study. Ann. Rheum. Dis. 52 7 (1993) 531-533
220. Rosenthal A.K., McLaughlin J.K., Gridley G., and Nyren O. Incidence of cancer among patients with systemic sclerosis. Cancer 76 5 (1995) 910-914
221. Rossi G.A., Bitterman P.B., Rennard S.I., Ferrans V.J., and Crystal R.G. Evidence for chronic inflammation as a component of the interstitial lung disease associated with progressive systemic sclerosis. Am. Rev. Respir. Dis. 131 4 (1985) 612-617
222. Rossi S.E., Erasmus J.J., McAdams H.P., Sporn T.A., and Goodman P.C. Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics 20 5 (2000) 1245-1259
223. Rothfield N., Kurtzman S., Vazques-Abad D., Charron C., Daniels L., and Greenberg B. Association of anti-topoisomerase I with cancer. Arthritis Rheum. 35 6 (1992) 724
224. Roumm A.D., and Medsger Jr. T.A. Cancer and systemic sclerosis. An epidemiologic study. Arthritis Rheum. 28 12 (1985) 1336-1340
225. Sakkas L.I., Tourtellotte C., Berney S., Myers A.R., and Platsoucas C.D. Increased levels of alternatively spliced interleukin 4 (IL-4delta2) transcripts in peripheral blood mononuclear cells from patients with systemic sclerosis. Clin. Diagn. Lab. Immunol. 6 5 (1999) 660-664
226. Santiago B., Galindo M., Rivero M., and Pablos J.L. Decreased susceptibility to Fas-induced apoptosis of systemic sclerosis dermal fibroblasts. Arthritis Rheum. 44 7 (2001) 1667-1676
227. Sato S., Nagaoka T., Hasegawa M., Nishijima C., and Takehara K. Elevated serum KL-6 levels in patients with systemic sclerosis: association with the severity of pulmonary fibrosis. Dermatology 200 3 (2000) 196-201
228. Sato S., Nagaoka T., Hasegawa M., Tamatani T., Nakanishi T., Takigawa M., and Takehara K. Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. J. Rheumatol. 27 1 (2000) 149-154
229. Schurawitzki H., Stiglbauer R., Graninger W., Herold C., Polzleitner D., Burghuber O.C., and Tscholakoff D. Interstitial lung disease in progressive systemic sclerosis: high-resolution CT versus radiography. Radiology 176 3 (1990) 755-759
230. Scussel-Lonzetti L., Joyal F., Raynauld J.P., Roussin A., Rich E., Goulet J.R., Raymond Y., and Senecal J.L. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 81 2 (2002) 154-167
231. Shahar I., Fireman E., Topilsky M., Grief J., Kivity S., Spirer Z., and Ben Efraim S. Effect of IL-6 on alveolar fibroblast proliferation in interstitial lung diseases. Clin. Immunol. Immunopathol. 79 3 (1996) 244-251
232. Shimizu S., Gabazza E.C., Hayashi T., Ido M., Adachi Y., and Suzuki K. Thrombin stimulates the expression of PDGF in lung epithelial cells. Am. J. Physiol. Lung. Cell Mol. Physiol. 279 3 (2000) L503-L510
233. Shi-Wen X., Denton C.P., McWhirter A., Bou-Gharios G., Abraham D.J., du Bois R.M., and Black C.M. Scleroderma lung fibroblasts exhibit elevated and dysregulated type I collagen biosynthesis. Arthritis Rheum. 40 7 (1997) 1237-1244
234. Sigurgeirsson B., Lindelof B., Edhag O., and Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N. Engl. J. Med. 326 6 (1992) 363-367
235. Silman A.J., and Jones S. What is the contribution of occupational environmental factors to the occurrence of scleroderma in men?. Ann. Rheum. Dis. 51 12 (1992) 1322-1324
236. Silver R.M., Heyes M.P., Maize J.C., Quearry B., Vionnet-Fuasset M., and Sternberg E.M. Scleroderma, fasciitis, and eosinophilia associated with the ingestion of tryptophan. N. Engl. J. Med. 322 13 (1990) 874-881
237. Silver R.M., Miller K.S., Kinsella M.B., Smith E.A., and Schabel S.I. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am. J. Med. 88 5 (1990) 470-476
238. Silver R.M., Warrick J.H., Kinsella M.B., Staudt L.S., Baumann M.H., and Strange C. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J. Rheumatol. 20 5 (1993) 838-844
239. Sime P.J., Marr R.A., Gauldie D., Xing Z., Hewlett B.R., Graham F.L., and Gauldie J. Transfer of tumor necrosis factor-alpha to rat lung induces severe pulmonary inflammation and patchy interstitial fibrogenesis with induction of transforming growth factor-beta1 and myofibroblasts. Am. J. Pathol. 153 3 (1998) 825-832
240. Simeon C.P., Armadans L., Fonollosa V., Solans R., Selva A., Villar M., Lima J., Vaque J., and Vilardell M. Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology (Oxford) 42 1 (2003) 71-75
241. Smith E.A., and Leroy E.C. A possible role for transforming growth factor-beta in systemic sclerosis. J. Invest. Dermatol. 95 6 (1990) 125S-127S
242. Southcott A.M., Jones K.P., Li D., Majumdar S., Cambrey A.D., Pantelidis P., Black C.M., Laurent G.J., Davies B.H., and Jeffery P.K. Interleukin-8. Differential expression in lone fibrosing alveolitis and systemic sclerosis. Am. J. Respir. Crit. Care Med. 151 5 (1995) 1604-1612
243. Spector J.I., and Zimbler H. Cyclophosphamide pneumonitis. N. Engl. J. Med. 307 4 (1982) 251
244. Spector J.I., Zimbler H., and Ross J.S. Early-onset cyclophosphamide-induced interstitial pneumonitis. JAMA 242 26 (1979) 2852-2854
245. Spencer-Green G., Alter D., and Welch H.G. Test performance in systemic sclerosis: anti-centromere and anti-Scl-70 antibodies. Am. J. Med. 103 3 (1997) 242-248
246. Steen V. Predictors of end stage lung disease in systemic sclerosis. Ann. Rheum. Dis. 62 2 (2003) 97-99
247. Steen V.D., and Medsger Jr. T.A. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum. 41 9 (1998) 1613-1619
248. Steen V.D., and Medsger Jr. T.A. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 43 11 (2000) 2437-2444
249. Steen V.D., Owens G.R., Redmond C., Rodnan G.P., and Medsger Jr. T.A. The effect of d-penicillamine on pulmonary findings in systemic sclerosis. Arthritis Rheum. 28 8 (1985) 882-888
250. Steen V.D., Powell D.L., and Medsger Jr. T.A. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum. 31 2 (1988) 196-203
251. Steen V.D., Conte C., Owens G.R., and Medsger Jr. T.A. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum. 37 9 (1994) 1283-1289
252. Steen V.D., Lanz Jr. J.K., Conte C., Owens G.R., and Medsger Jr. T.A. Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum. 37 9 (1994) 1290-1296
253. Steen V.D., Oddis C.V., Conte C.G., Janoski J., Casterline G.Z., and Medsger Jr. T.A. Incidence of systemic sclerosis in Allegheny County. Pennsylvania. A twenty-year study of hospital-diagnosed cases, 1963-1982. Arthritis Rheum. 40 3 (1997) 441-445
254. Stockton D., Doherty V.R., and Brewster D.H. Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br. J. Cancer 85 1 (2001) 41-45
255. Suga M., Iyonaga K., Ichiyasu H., Saita N., Yamasaki H., and Ando M. Clinical significance of MCP-1 levels in BALF and serum in patients with interstitial lung diseases. Eur. Respir. J. 14 2 (1999) 376-382
256. Susol E., Rands A.L., Herrick A., McHugh N., Barrett J.H., Ollier W.E., and Worthington J. Association of markers for TGFbeta3, TGFbeta2 and TIMP1 with systemic sclerosis. Rheumatology (Oxford) 39 12 (2000) 1332-1336
257. Tabuenca J.M. Toxic-allergic syndrome caused by ingestion of rapeseed oil denatured with aniline. Lancet 2 (1981) 567-568
258. Takahashi H., Kuroki Y., Tanaka H., Saito T., Kurokawa K., Chiba H., Sagawa A., Nagae H., and Abe S. Serum levels of surfactant proteins A and D are useful biomarkers for interstitial lung disease in patients with progressive systemic sclerosis. Am. J. Respir. Crit. Care Med. 162 1 (2000) 258-263
259. Talbott J.H., and Barrocas M. Carcinoma of the lung in progressive systemic sclerosis: a tabular review of the literature and a detailed report of the roentgenographic changes in two cases. Semin. Arthritis Rheum. 9 3 (1980) 191-217
260. Tan F.K., Stivers D.N., Arnett F.C., Chakraborty R., Howard R., and Reveille J.D. HLA haplotypes and microsatellite polymorphisms in and around the major histocompatibility complex region in a Native American population with a high prevalence of scleroderma (systemic sclerosis). Tissue Antigens 53 1 (1999) 74-80
261. Tan F.K., Wang N., Kuwana M., Chakraborty R., Bona C.A., Milewicz D.M., and Arnett F.C. Association of fibrillin 1 single-nucleotide polymorphism haplotypes with systemic sclerosis in Choctaw and Japanese populations. Arthritis Rheum. 44 4 (2001) 893-901
262. Topilow A.A., Rothenberg S.P., and Cottrell T.S. Interstitial pneumonia after prolonged treatment with cyclophosphamide. Am. Rev. Respir. Dis. 108 1 (1973) 114-117
263. Tormey V.J., Bunn C.C., Denton C.P., and Black C.M. Anti-fibrillarin antibodies in systemic sclerosis. Rheumatology (Oxford) 40 10 (2001) 1157-1162
264. Tramposch H.D., Smith C.D., Senecal J.L., and Rothfield N. A long-term longitudinal study of anticentromere antibodies. Arthritis Rheum. 27 2 (1984) 121-124
265. Vaillant P., Menard O., Vignaud J.M., Martinet N., and Martinet Y. The role of cytokines in human lung fibrosis. Monaldi. Arch. Chest Dis. 51 2 (1996) 145-152
266. Vancheeswaran R., Magoulas T., Efrat G., Wheeler-Jones C., Olsen I., Penny R., and Black C.M. Circulating endothelin-1 levels in systemic sclerosis subsets-a marker of fibrosis or vascular dysfunction?. J. Rheumatol. 21 10 (1994) 1838-1844
267. van Nunen S.A., Gatenby P.A., and Basten A. Post-mammoplasty connective tissue disease. Arthritis Rheum. 25 6 (1982) 694-697
268. Varai G., Earle L., Jimenez S.A., Steiner R.M., and Varga J. A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease. J. Rheumatol. 25 7 (1998) 1325-1329
269. Varga J., and Bashey R.I. Regulation of connective tissue synthesis in systemic sclerosis. Int. Rev. Immunol. 12 2-4 (1995) 187-199
270. Varga J., Rosenbloom J., and Jimenez S.A. Transforming growth factor beta (TGF beta) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts. Biochem. J. 247 3 (1987) 597-604
271. Vaughan M.B., Howard E.W., and Tomasek J.J. Transforming growth factor-beta1 promotes the morphological and functional differentiation of the myofibroblast. Exp. Cell. Res. 257 1 (2000) 180-189
272. Vazquez-Abad D., Russell C.A., Cusick S.M., Earnshaw W.C., and Rothfield N.F. Longitudinal study of anticentromere and antitopoisomerase-I isotypes. Clin. Immunol. Immunopathol. 74 3 (1995) 257-270
273. Veltman G., Lange C.E., Juhe S., Stein G., and Bachner U. Clinical manifestations and course of vinyl chloride disease. Ann. N. Y. Acad. Sci. 246 (1975) 6-17
274. Wakata N., Kurihara T., Saito E., and Kinoshita M. Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int. J. Dermatol. 41 11 (2002) 729-734
275. Wallaert B. Subclinical alveolitis in immunologic systemic disorders. Lung 168 (1990) 974-983
276. Wallaert B., Hatron P.Y., Grosbois J.M., Tonnel A.B., Devulder B., and Voisin C. Subclinical pulmonary involvement in collagen-vascular diseases assessed by bronchoalveolar lavage. Relationship between alveolitis and subsequent changes in lung function. Am. Rev. Respir. Dis. 133 4 (1986) 574-580
277. Wallaert B., Bart F., Aerts C., Ouaissi A., Hatron P.Y., Tonnel A.B., and Voisin C. Activated alveolar macrophages in subclinical pulmonary inflammation in collagen vascular diseases. Thorax 43 1 (1988) 24-30
278. Weiner E.S., Hildebrandt S., Senecal J.L., Daniels L., Noell S., Joyal F., Roussin A., Earnshaw W., and Rothfield N.F. Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud's disease. A prospective study. Arthritis Rheum. 34 1 (1991) 68-77
279. Wells A.U., and du Bois R.M. Bronchiolitis in association with connective tissue disorders. Clin. Chest Med. 14 4 (1993) 655-666
280. Wells A.U., Hansell D.M., Corrin B., Harrison N.K., Goldstraw P., Black C.M., and du Bois R.M. High resolution computed tomography as a predictor of lung histology in systemic sclerosis. Thorax 47 9 (1992) 738-742
281. Wells A.U., Hansell D.M., Harrison N.K., Lawrence R., Black C.M., and du Bois R.M. Clearance of inhaled 99mTc-DTPA predicts the clinical course of fibrosing alveolitis. Eur. Respir. J. 6 6 (1993) 797-802
282. Wells A.U., Hansell D.M., Rubens M.B., Cullinan P., Black C.M., and du Bois R.M. The predictive value of appearances on thin-section computed tomography in fibrosing alveolitis. Am. Rev. Respir. Dis. 148 4 Pt 1 (1993) 1076-1082
283. Wells A.U., Cullinan P., Hansell D.M., Rubens M.B., Black C.M., Newman-Taylor A.J., and du Bois R.M. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am. J. Respir. Crit. Care. Med. 149 6 (1994) 1583-1590
284. Wells A.U., Hansell D.M., Rubens M.B., Cullinan P., Haslam P.L., Black C.M., and du Bois R.M. Fibrosing alveolitis in systemic sclerosis. Bronchoalveolar lavage findings in relation to computed tomographic appearance. Am. J. Respir. Crit. Care Med. 150 2 (1994) 462-468
285. Wells A.U., Hansell D.M., Rubens M.B., Cailes J.B., Black C.M., and du Bois R.M. Functional impairment in lone cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a comparison. Am. J. Respir. Crit. Care Med. 155 5 (1997) 1657-1664
286. Wells A.U., Hansell D.M., Rubens M.B., King A.D., Cramer D., Black C.M., and du Bois R.M. Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to extent of disease on computed tomography. Arthritis Rheum. 40 7 (1997) 1229-1236
287. Wells A.U., Hansell D.M., Haslam P.L., Rubens M.B., Cailes J., Black C.M., and du Bois R.M. Bronchoalveolar lavage cellularity: lone cryptogenic fibrosing alveolitis compared with the fibrosing alveolitis of systemic sclerosis. Am. J. Respir. Crit. Care Med. 157 5 Pt 1 (1998) 1474-1482
288. Wells A.U., Desai S.R., Rubens M.B., Goh N.S., Cramer D., Nicholson A.G., Colby T.V., du Bois R.M., and Hansell D.M. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am. J. Respir. Crit. Care Med. 167 7 (2003) 962-969
289. White B., Moore W.C., Wigley F.M., Xiao H.Q., and Wise R.A. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann. Intern. Med. 132 12 (2000) 947-954
290. Whyte J., Artlett C., Harvey G., Stephens C.O., Welsh K., Black C., Maddison P.J., and McHugh N.J. HLA-DQB1 associations with anti-topoisomerase-1 antibodies in patients with systemic sclerosis and their first degree relatives. United Kingdom Systemic Sclerosis Study Group. J. Autoimmun. 7 4 (1994) 509-520
291. Wiedemann H.P., and Matthay R.A. Pulmonary manifestations of the collagen vascular diseases. Clin. Chest Med. 10 4 (1989) 677-722
292. Wrana J.L., and Attisano L. The Smad pathway. Cytokine Growth Factor Rev. 11 1-2 (2000) 5-13
293. Yamakage A., Kikuchi K., Smith E.A., Leroy E.C., and Trojanowska M. Selective upregulation of platelet-derived growth factor alpha receptors by transforming growth factor beta in scleroderma fibroblasts. J. Exp. Med. 175 5 (1992) 1227-1234
294. Yamamoto T., Eckes B., and Krieg T. High expression and autoinduction of monocyte chemoattractant protein-1 in scleroderma fibroblasts. Eur. J. Immunol. 31 10 (2001) 2936-2941
295. Yamane K., Ihn H., Kubo M., Yazawa N., Kikuchi K., Soma Y., and Tamaki K. Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. J. Rheumatol. 27 4 (2000) 930-934
296. Yanaba K., Hasegawa M., Hamaguchi Y., Fujimoto M., Takehara K., and Sato S. Longitudinal analysis of serum KL-6 levels in patients with systemic sclerosis: association with the activity of pulmonary fibrosis. Clin. Exp. Rheumatol. 21 4 (2003) 429-436
297. Yang Y., Fujita J., Tokuda M., Bandoh S., and Ishida T. Lung cancer associated with several connective tissue diseases: with a review of literature. Rheumatol. Int. 21 3 (2001) 106-111
298. Young V., Ho M., Vosper H., Belch J.J., and Palmer C.N. Elevated expression of the genes encoding TNF-alpha and thromboxane synthase in leucocytes from patients with systemic sclerosis. Rheumatology (Oxford) 41 8 (2002) 869-875
299. Young-Min S.A., Beeton C., Laughton R., Plumpton T., Bartram S., Murphy G., Black C., and Cawston T.E. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls. Ann. Rheum. Dis 60 9 (2001) 846-851
300. Zhang H.Y., and Phan S.H. Inhibition of myofibroblast apoptosis by transforming growth factor beta(1). Am. J. Respir. Cell Mol. Biol. 21 6 (1999) 658-665
301. Zhang K., Gharaee-Kermani M., Jones M.L., Warren J.S., and Phan S.H. Lung monocyte chemoattractant protein-1 gene expression in bleomycin-induced pulmonary fibrosis. J. Immunol. 153 10 (1994) 4733-4741
302. Zhang K., Flanders K.C., and Phan S.H. Cellular localization of transforming growth factor-beta expression in bleomycin-induced pulmonary fibrosis. Am. J. Pathol. 147 2 (1995) 352-361